

Ref. No: 1542
Date: 12/02/25
Subject: High-cost drugs in ophthalmology

REQUEST

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

1. For the 4 months from September to December 2024, how many unique* patients received the following intra-vitreous treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab – Lucentis

Ranibizumab Biosimilar

*Please count a patient only once for any treatment, regardless of how many injections or implants they may have received

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab – Lucentis

Ranibizumab Biosimilar

RESPONSE

MWL Response

1. For the 4 months from September to December 2024, how many unique* patients received the following intra-vitreous treatments for any eye condition:

Aflibercept - <5

Bevacizumab - 0

Brolucizumab - 0

Dexamethasone - 64

Faricimab - 0

Ranibizumab – Lucentis - 0

Ranibizumab Biosimilar - <5

Due to the low number of patients receiving some of the above medications which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).